LAVA Therapeutics raises $83 million

Country

Netherlands

LAVA Therapeutics BV, a four-year old company investigating bispecific antibodies directed against gamma-delta T cells, has raised $83 million to bring its programmes into clinical development for cancer. The oversubscribed Series C financing round was co-led by Novo Ventures, the venture arm of Novo Holdings, and Sanofi Ventures. Nanna Lüneborg, a partner at Novo Ventures, will join the company’s board of directors.